Enasidenib

Idhifa

Treatment Description

Enasidenib is an IDH2 inhibitor that is FDA approved to treat acute myeloid leukemia in patients with a specific IDH2 mutations, and being studied for use in other blood cancers.

Participating Centers

There are 146 centers running trials with this treatment. Enter a location below to find the closest center.